Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones

European Journal of Medicinal Chemistry

Volumn 112, Issue , 2016, Pages 180-195

  Kaminskyy, Danylo ^a   Den Hartog, Gertjan J M ^b   Wojtyra, Magdalena ^a   Lelyukh, Maryan ^a   Gzella, Andrzej ^c   Bast, Aalt ^b   Lesyk, Roman ^a  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Amino amino thiazolidinones; Antifibrotic activity; Antiproliferative effects; One pot method; Superoxide radicals; Synthesis

Indexed keywords

2 (6 METHYLBENZOTHIAZOL 2 YLIMINO)THIAZOLIDIN 4 ONE; 2 (N' PYRIDIN 3 YLMETHYLENEHYDRAZONO)THIAZOLIDIN 4 ONE; 2 [3 FURAN 2 YLMETHYL 2 [(2 METHYL 3 PHENYLALLYLIDENE)HYDRAZONO]THIAZOLIDIN 4 ONE 5 YL] N (3 TRIFLUOROMETHYLPHENYL)ACETAMIDE; 2 [5 (4 METHOXYPHENYL) [1,3,4]OXADIAZOL 2 YLIMINO]THIAZOLIDIN 4 ONE; 2 [5 [5 (4 CHLOROBENZYLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENEAMINO] [1,3,4]THIADIAZOL 2 YLSULFANYL] N (2 METHOXYPHENYL)ACETAMIDE; 3 (4 ETHOXYPHENYL) 2 (4 ETHOXYPHENYLIMINO) 5 [2 (4 METHOXYPHENYL) 2 OXOETHYL]THIAZOLIDIN 4 ONE; 3 FURAN 2 YLMETHYL 2 (PYRIDIN 3 YLMETHYLENEHYDRAZONO)THIAZOLIDIN 4 ONE; 4 THIAZOLIDINONE DERIVATIVE; 5 (2 HYDROXYETHYL) 2 (N' PYRIDIN 3 YLMETHYLENEHYDRAZONO)THIAZOLIDIN 4 ONE; 5 (2 METHYL 3 PHENYLALLYLIDENE) 2 [(4 HYDROXYPHENYL)METHYLAMINO] THIAZOL 4(5H) ONE; 5 (3 ETHOXY 4 HYDROXYBENZYLIDENE) 2 (6 METHYLBENZOTHIAZOL 2 YLAMINO)THIAZOL 4(5H) ONE; 5 (3 HYDROXYBENZYLIDENE) 2 (4 HYDROXYPHENYLAMINO)THIAZOL 4(5H) ONE; 5 (3 PHENYLALLYLIDENE) 2 (4 HYDROXYPHENYLAMINO)THIAZOL 4(5H) ONE; 5 (4 CHLOROBENZYLIDENE) 2 (4 HYDROXYPHENYLAMINO)THIAZOL- 4(5H) ONE; 5 (4 CHLOROBENZYLIDENE) 2 (THIAZOL 2 YLIMINO)THIAZOLIDIN 4 ONE; 5 (4 DIMETHYLAMINOBENZYLIDENE) 2 [5 (4 METHOXYPHENYL) [1,3,4]OXADIAZOL 2 YLIMINO]THIAZOLIDIN 4 ONE; 5 BENZYLIDENE 2 (4 HYDROXYPHENYLAMINO)THIAZOL 4(5H) ONE; 5 ENE 2 AMINO(IMINO) 4 THIAZOLIDINONE DERIVATIVE; 5 ETHYL 2 (N' PYRIDIN 3 YLMETHYLENEHYDRAZONO)THIAZOLIDIN 4 ONE; 5 ETHYL 3 FURAN 2 YLMETHYL 2 (PYRIDIN 3 YLMETHYLENEHYDRAZONO)THIAZOLIDIN 4 ONE; 5 METHYL 2 (N' PYRIDIN 3 YLMETHYLENHYDRAZONO)THIAZOLIDIN 4 ONE; 5 [2 (4 FLUOROPHENYL) 2 OXOETHYL] 2 (4 HYDROXYPHENYLAMINO) 4,5 DIHYDROTHIAZOL 4 ONE; 5 [2 CHLORO 3 (4 NITROPHENYL)ALLYLIDENE] 2 [(4 HYDROXYPHENYL)METHYLAMINO]THIAZOL 4(5H) ONE; ANTIFIBROTIC AGENT; ANTINEOPLASTIC AGENT; N (2 METHOXYPHENYL) 2 [5 (4 OXOTHIAZOLIDIN 2 YLIDENEAMINO) [1,3,4]THIADIAZOL 2 YLSULFANYL]ACETAMIDE; N (4 BROMOPHENYL) 2 [2 (3 HYDROXYPHENYLAMINO) 4 OXO 4,5 DIHYDROTHIAZOL 5 YL]ACETAMIDE; N (4 BROMOPHENYL) 2 [2 (4 SULFAMOYLPHENYLAMINO) 4 OXO 4,5 DIHYDROTHIAZOL 5 YL]ACETAMIDE; N (4 CHLOROPHENYL) 2 [5 (4 OXOTHIAZOLIDIN 2 YLIDENEAMINO) [1,3,4]THIADIAZOL 2 YLSULFANYL]ACETAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMINE; SUPEROXIDE; THIAZOLIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYCLOCONDENSATION; CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FETUS; FIBROBLAST; HUMAN; HUMAN CELL; KNOEVENAGEL CONDENSATION; TAUTOMER; X RAY ANALYSIS; AMINATION; CELL LINE; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; METABOLISM; MOLECULAR MODEL; X RAY CRYSTALLOGRAPHY;

AMINATION; ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMINES; LUNG; MODELS, MOLECULAR; SUPEROXIDES; THIAZOLIDINES;

EID: 84958550058     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.02.011     Document Type: Article

References (72)

1. M.E. Welsch, S.A. Snyder, and B.R. Stockwell Privileged scaffolds for library design and drug discovery Curr. Opin. Chem. Biol. 14 2010 1 15 10.1016/j.cbpa.2010.02.018
2. T. Tomašic, and L. Peterlin Mašic Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation Expert Opin. Drug Dis. 7 7 2012 549 560 10.1517/17460441.2012.688743
3. A.C. Tripathi, S.J. Gupta, G.N. Fatima, P.K. Sonar, A. Verma, and S.K. Saraf 4-Thiazolidinones: the advances continue Eur. J. Med. Chem. 72 2014 52 77 10.1016/j.ejmech.2013.11.017
4. R.B. Lesyk, and B.S. Zimenkovsky 4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry Curr. Org. Chem. 8 16 2004 1547 1577 10.2174/1385272043369773
5. V. Asati, D.K. Mahapatra, and S.K. Bharti Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: potential anticancer agents Eur. J. Med. Chem. 87 2014 814 833 10.1016/j.ejmech.2014.10.025
6. V.S. Jain, D.K. Vora, and C.S. Ramaa Thiazolidine-2,4-diones: progress towards multifarious applications Bioorg. Med. Chem. 27 7 2013 1599 1620 10.1016/j.bmc.2013.01.029
7. K.S.S. Kumar, A. Hanumappa, M. Hegde, K.H. Narasimhamurthy, S.C. Raghavan, and K.S. Rangappa Synthesis and antiproliferative effect of novel 4-thiazolidinone-, pyridine- and piperazine-based conjugates on human leukemic cells Eur. J. Med. Chem. 81 2014 341 349 10.1016/j.ejmech.2014.05.009
8. Y. Zhang, S. Wang, S. Wu, S. Zhu, G. Dong, Z. Miao, J. Yao, W. Zhang, C. Sheng, and W. Wang Facile construction of structurally diverse thiazolidinedione-derived compounds via divergent stereoselective cascade organocatalysis and their biological exploratory studies ACS Comb. Sci. 15 6 2013 298 308 10.1021/co400022r
9. R. Maccari, R.M. Vitale, R. Ottanà, M. Rocchiccioli, A. Marrazzo, V. Cardile, A.C.E. Graziano, P. Amodeo, U. Mura, and A. Del Corso Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents Eur. J. Med. Chem. 81 2014 1 14 10.1016/j.ejmech.2014.05.003
10. D. Kaminskyy, B. Zimenkovsky, and R. Lesyk Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives Eur. J. Med. Chem. 44 9 2009 3627 3636 10.1016/j.ejmech.2009.02.023
11. D. Kaminskyy, D. Khyluk, O. Vasylenko, L. Zaprutko, and R. Lesyk A facile synthesis and anticancer activity evaluation of spiro[thiazolidinone-isatin] conjugates Sci. Pharm. 79 4 2011 763 777 10.3797/scipharm.1109-14
12. D. Kaminskyy, I. Subtel'na, B. Zimenkovsky, O. Karpenko, A. Gzella, and R. Lesyk Synthesis and evaluation of anticancer activity of 5-ylidene-4-aminothiazol-2(5H)-one derivatives Med. Chem. 11 6 2015 517 530 10.2174/1573406411666150211112049
13. J.B. Baell, and G.A. Holloway New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 53 2010 2719 2740 10.1021/jm901137j
14. T. Mendgen, C. Steuer, and C.D. Klein Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry J. Med. Chem. 55 2012 743 753 10.1021/jm201243p
15. P.J. Hajduk, and J. Greer A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6.3 2007 211 219 10.1038/nrd2220
16. H.J. Forman, K.J. Davies, and F. Ursini How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavengingin vivo Free Rad. Biol. Med. 66 2014 24 35 10.1016/j.freeradbiomed.2013.05.045
17. K. Omar, A. Geronikaki, P. Zoumpoulakis, C. Camoutsis, M. Socovic, A. Ciric, and J. Glamoclija Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs Bioorg. Med. Chem. 18 2010 426 432 10.1016/j.bmc.2009.10.041
18. R. Ottana, R. Maccari, M.L. Barreca, G. Bruno, A. Rotondo, A. Rossi, G. Chiricosta, R. Paola, L. Sautebin, S. Cuzzocread, and M.G. Vigorita 5-Arylidene-2-imino-4-thiazolidinones: design and synthesis of novel anti-inflammatory agents Bioorg. Med. Chem. 13 2005 4243 5242 10.1016/j.bmc.2005.04.058
19. I. Subtel'na, D. Atamanyuk, E. Szymanska, K. Kieć-Kononowicz, B. Zimenkovsky, O. Vasylenko, A. Gzella, and R. Lesyk Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity Bioorg. Med. Chem. 14 2010 5090 5102 10.1016/j.bmc.2010.05.073
20. R. Ottanà, S. Carotti, R. Maccari, I. Landini, G. Chiricosta, B. Caciagli, M. Vigorita, and E. Mini In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I Bioorg. Med. Chem. Lett. 15 17 2005 3930 3933 10.1016/j.bmcl.2005.05.093
21. F. Teraishi, S. Wu, J. Sasaki, L. Zhang, H.B. Zhu, J.J. Davis, and B. Fang P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone] J. Pharmacol. Exp. Ther. 314 1 2005 355 362 10.1124/jpet.105.085654
22. H. Zhou, S. Wu, S. Zhai, A. Liu, Y. Sun, R. Li, Y. Zhang, S. Ekins, P.W. Swaan, B. Fang, B. Zhang, and B. Yan Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells J. Med. Chem. 51 5 2008 1242 1251 10.1021/jm7012024
23. 3 antagonists as novel anticancer agents J. Med. Chem. 49 15 2006 4526 4534 10.1021/jm051296s
24. S. Chen, L. Chen, N.T. Le, C. Zhao, A. Sidduri, J.P. Lou, C. Michoud, L. Portland, N. Jackson, J.J. Liu, F. Konzelmann, F. Chi, C. Tovar, Q. Xiang, Y. Chen, Y. Wen, and L.T. Vassilev Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors Bioorg. Med. Chem. Lett. 17 8 2007 2134 2138 10.1016/j.bmcl.2007.01.081
25. A. Kryshchyshyn, D. Kaminskyy, P. Grellier, and R. Lesyk Trends in research of antitrypanosomal agents among synthetic heterocycles Eur. J. Med. Chem. 85 2014 51 64 10.1016/j.ejmech.2014.07.092
26. H. Sugiura, T. Ichikawa, X. Liu, T. Kobayashi, X.Q. Wang, S. Kawasaki, S. Togo, K. Kamio, L. Mao, Y. Ann, M. Ichinose, and S.I. Rennard N-acetyl-L-cysteine inhibits TGF-beta1-induced profibrotic responses in fibroblasts Pulm. Pharmacol. Ther. 22 6 2009 487 491 10.1016/j.pupt.2009.04.002
27. R. Kalluri, and M. Zeisberg Fibroblasts in cancer Nat. Rev. Cancer 6 2006 392 401 10.1038/nrc1877
28. N. Turner, and R. Grose Fibroblast growth factor signalling: from development to cancer Nat. Rev. Cancer 10.2 2010 116 129 10.1038/nrc2780
29. A. Bast, A.R. Weseler, G.R. Haenen, and G.J. den Hartog Oxidative stress and antioxidants in interstitial lung disease Curr. Opin. Pulm. Med. 16 5 2010 516 520 10.1097/MCP.0b013e32833c645d
30. T.E. King Jr., W.Z. Bradford, S. Castro-Bernardini, E.A. Fagan, I. Glaspole, M.K. Glassberg, M.K. Glassberg, E. Gorina, P.M. Hopkins, D. Kardatzke, L. Lancaster, D.J. Lederer, S.D. Nathan, C.A. Pereira, S.A. Sahn, R. Sussman, J.J. Swigris, and P.W. Noble A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N. Engl. J. Med. 370 22 2014 2083 2092 10.1056/NEJMoa1402582
31. V. Cottin, and T. Maher Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Eur. Respir. Rev. 24 135 2015 58 64 10.1183/09059180.00011514
32. T.R. Scott, S. Francine, D. Jenkins, Pharmaceutical compositions to treat fibrosis, Fate Therapeutics, Inc., Pat. US20130274215, Appl. No 13/639,644, 2011.
33. U.E. Lee, and S.L. Friedman Mechanisms of hepatic fibrogenesis Best. Pract. Res. Cl. Gastroenter 25 2 2011 195 206 10.1016/j.bpg.2011.02.005
34. S. Dooley, and P. Ten Dijke TGF-β in progression of liver disease Cell Tiss. Res. 347 1 2012 245 256 10.1007/s00441-011-1246-y
35. L. Richeldi, R.M. du Bois, G. Raghu, A. Azuma, K.K. Brown, U. Costabel, V. Cottin, K.R. Flaherty, D.M. Hansell, Y. Inoue, D. Soon Kim, M. Kolb, A.G. Nicholson, P.W. Noble, M. Selman, H. Taniguchi, M. Brun, F. Le Maulf, M. Girard, S. Stowasser, R. Schlenker-Herceg, B. Disse, and H.R. Collard Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N. Engl. J. Med. 370 2014 2071 2082 10.1056/NEJMoa1402584
36. Q. Zhang, X. Liu, X. Li, C. Li, H. Zhou, and B. Yan Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino)thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model J. Pharmacol. Sci. 122 2013 223 231 10.1254/jphs.13064FP
37. S. Wu, W. Guo, F. Teraishi, J. Pang, K. Kaluarachchi, L. Zhang, Davis, F. Dong, B. Yan, and B. Fang Anticancer activity of 5-benzylidene-2-phenylimino-1,3-thiazolidin-4-one (BPT) analogs Med. Chem. 2 6 2006 597 605
38. M. Sala, A. Chimento, C. Saturnino, I.M. Gomez-Monterrey, S. Musella, A. Bertamino, C. Milite, M.S. Sinicropi, A. Caruso, R. Sirianni, P. Tortorella, E. Novellino, P. Campiglia, and V. Pezzi Synthesis and cytotoxic activity evaluation of 2,3-thiazolidin-4-one derivatives on human breast cancer cell lines Bioorg. Med. Chem. Lett. 23 17 2013 4990 4995 10.1016/j.bmcl.2013.06.051
39. G. Nagalakshmi, T.K. Maity, and B.C. Maiti Synthesis, characterization and antiproliferative activity of some novel 2-(substitutedphenyl)-5-methyl-3-(phenylamino)-1,3-thiazolidin-4-ones Pharmacologyonline 1 2011 1228 1246 http://www.unisa.it/uploads/4940/126.maiti.pdf
40. G.J. den Hartog, S. Qi, J.H. van Tilburg, G.H. Koek, and A. Bast Superoxide anion radicals activate hepatic stellate cells after entry through chloride channels: a new target in liver fibrosis Eur. J. Pharmacol. 724 5 2014 140 144 10.1016/j.ejphar.2013.12.033
41. S. Qi, G.J. den Hartog, and A. Bast Superoxide radicals increase transforming growth factor-beta1 and collagen release from human lung fibroblasts via cellular influx through chloride channels Toxicol. Appl. Pharmacol. 237 1 2009 111 118 10.1016/j.taap.2009.02.019
42. K.O. Semen, G.J.M. den Hartog, D.V. Kaminskyy, T.V. Sirota, N.G.A.A. Maij, O.P. Yelisyeyeva, and A. Bast Redox modulation by amaranth oil in human lung fibroblasts Nat. Prod. Chem. Res. 2 122 2013 2 10.4172/2329-6836.1000122
43. D. Havrylyuk, L. Mosula, B. Zimenkovsky, O. Vasylenko, A. Gzella, and R. Lesyk Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety Eur. J. Med.Chem. 45 11 2010 5012 5021 10.1016/j.ejmech.2010.08.008
44. A. Mobinikhaledi, and A.K. Amiri Natural eutectic salts catalyzed one-pot synthesis of 5-arylidene-2-imino-4-thiazolidinones Res. Chem. Intermed. 39 2013 1491 1498 10.1007/s11164-012-0707-6
45. D. Havrylyuk, B. Zimenkovsky, O. Vasylenko, A. Gzella, and R. Lesyk Synthesis of new 4-thiazolidinone-, pyrazoline-, and isatin-based conjugates with promising antitumor activity J. Med. Chem. 55 2012 8630 8641 10.1021/jm300789g
46. R. Lesyk, O. Vladzimirska, S. Holota, L. Zaprutko, and A. Gzella New 5-substituted thiazolo[3,2-b][1,2,4]triazol-6-ones: synthesis and anticancer evaluation Eur. J. Med. Chem. 42 5 2007 641 648 10.1016/j.ejmech.2006.12.006
47. M.H. Bolli, S. Abele, C. Binkert, R. Bravo, S. Buchmann, D. Bur, J. Gatfield, P. Hess, C. Kohl, C. Mangold, B. Mathys, K. Menyhart, C. Muller, O. Nayler, M. Scherz, G. Schmidt, V. Sippel, B. Steiner, D. Strasser, A. Treiber, and T. Weller 2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists J. Med. Chem. 53 10 2010 4198 4211 10.1021/jm100181s
48. A.K. Gzella, M. Kowiel, A. Suseł, M.N. Wojtyra, and R. Lesyk Heterocyclic tautomerism: reassignment of two crystal structures of 2-amino-1,3-thiazolidin-4-one derivatives Acta Crystallorg. C 70 8 2014 812 816 10.1107/S2053229614015162
49. A. Nowaczyk, M. Kowiel, A. Gzella, Ł. Fijałkowski, V. Horishny, and R. Lesyk Conformational space and vibrational spectra of 2-[(2,4-dimethoxyphenyl)amino]-1,3-thiazolidin-4-one J. Mol. Model 20 8 2014 1 9 10.1007/s00894-014-2366-6
50. D. Havrylyuk, B. Zimenkovsky, O. Vasylenko, L. Zaprutko, A. Gzella, and R. Lesyk Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity Eur. J. Med. Chem. 44 4 2009 1396 1404 10.1016/j.ejmech.2008.09.032
51. F.H. Allen The Cambridge Structural Database: a quarter of a million crystal structures and rising Acta Cryst. Sect. B 58 2002 380 388 10.1107/S0108768102003890
52. F.H. Allen, O. Kennard, D.G. Watson, L. Brammer, A.G. Orpen, and R. Taylor Typical interatomic distances: organic compounds J. Chem. Soc. Perkin Trans. 2 84 1987 1 19 10.1107/97809553602060000621
53. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, and M. Boyd Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Nat. Cancer Inst. 83 1991 757 766 10.1093/jnci/83.11.757
54. M.R. Boyd, and K.D. Paull Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen Drug Dev. Res. 34 1995 91 109 10.1002/ddr.430340203
55. M.R. Boyd B.A. Teicher, Cancer Drug Discovery and Development 1997 Humana Press Totowa, New York 23 43 Chap. 2
56. M. Kirkova, M. Atanassova, and E. Russanov Effects of cimetidine and its metal complexes on nitroblue tetrazolium and ferricytochrome c reduction by superoxide radicals Gen. Pharmacol. 33 3 1999 271 276 10.1016/S0306-3623(99)00015-4
57. A.A. Geronikaki, E.P. Pitta, and K.S. Liaras Thiazoles and thiazolidinones as antioxidants Curr. Med. Chem. 20 36 2013 4460 4480
58. X. Li, P. Fang, J. Mai, E.T. Choi, H. Wang, and X.F. Yang Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers J. Hematol. Oncol. 6 2013 19 10.1186/1756-8722-6-19
59. M.M. Hippert, P.S. O'Toole, and A. Thorburn Autophagy in cancer: good, bad, or both? Cancer Res. 66 2006 9349 9351 10.1158/0008-5472
60. G. Revelant, S. Huber-Villaume, S. Dunand, G. Kirsch, H. Schohn, and S. Hesse Synthesis and biological evaluation of novel 2-heteroarylimino-1,3-thiazolidin-4-ones as potential anti-tumor agents Eur. J. Med. Chem. 94 2015 102 112 10.1016/j.ejmech.2015.02.053
61. B.T. Moorthy, S. Ravi, M. Srivastava, K.K. Chiruvella, H. Hemlal, O. Joy, and S.C. Raghavan Novel rhodanine derivatives induce growth inhibition followed by apoptosis Bioorg. Med. Chem. Lett. 20 21 2010 6297 6301 10.1016/j.bmcl.2010.08.084
62. S.K. Niture, J.W. Kaspar, J. Shen, and A.K. Jaiswal Nrf2 signaling and cell survival Toxicol. Appl. Pharmacol. 244 2010 37 42 10.1016/j.taap.2009.06.009
63. A.P. Grischuk, I.D. Komaritsa, and S.N. Baranov 4-Thionazolidones, derivatives and analogs Chem. Heterocycl. Compd. 5 1966 541 543 10.1007/BF00477515
64. P. Vicini, L. Amoretti, M. Chiavarini, and M. Impicciatore Synthesis and local anesthetic activity of alkylaminoacyl derivatives of 3-amino-1,2-benzisothiazoles Farmaco 45 9 1990 933 943
65. R. Lesyk, B. Zimenkovsky, I. Subtelna, I. Nektegayev, and G. Kazmirchuk Synthesis and antiinflammatory activity of some 2-arylamino-2-thiazoline-4-ones Acta Pol. Pharm. 60 6 2003 457 466 http://www.ptfarm.pl/pub/File/Acta-Poloniae/2003/6/457.pdf
66. P. Vicini, A. Geronikaki, K. Anastasia, M. Incerti, and F. Zani Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones Bioorg. Med. Chem. 14 11 2006 3859 3864 10.1016/j.bmc.2006.01.043
67. G. Sheldrick A short history of SHELX Acta Crystallogr. Sect. A 64 2008 112 122 10.1107/S0108767307043930
68. L.J. Farrugia WinGX and ORTEP for Windows: an update J. Appl. Cryst. 45 2012 849 854 10.1107/S0021889812029111
69. O.V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, and H. Puschmann OLEX2: a complete structure solution, refinement and analysis program J. Appl. Cryst. 42 2009 229 341 10.1107/S0021889808042726
70. A.L. Spek Structure validation in chemical crystallography Acta Cryst. Sect. D. 65 2009 148 155 10.1107/S090744490804362X
71. H. Jacobs, A. Bast, G.J. Peters, W.J. van der Vijgh, and G.R. Haenen The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-kappa B Br. J. Cancer 104 2011 437 440 10.1038/sj.bjc.6606065
72. N. Ke, X. Wang, X. Xu, and Y.A. Abassi The xCELLigence system for real-time and label-free monitoring of cell viability Methods Mol. Biol. 740 2011 33 43 10.1007/978-1-61779-108-6-6